Products
Zamubafusp Biosimilar Antibody Fusion Protein (Immunoglobulin Light Chain Neoepitope) for Research
Cat No.: GMP-Bios-INN-1471
Anti-Human variable immunoglobulin light chain (N-terminal cryptic neo-epitope) therapeutic antibody (Pre-made Zamubafusp biosimilar,Antibody Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Zamubafusp (development code AT-02) is a humanized antibody fusion protein targeting a cryptic neo-epitope of the immunoglobulin light chain, fused to a pan-amyloid-binding peptide. It is developed by Attralus for AL amyloidosis. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1471-1mg | 1mg | 3090 |
| GMP-Bios-INN-1471-10mg | 10mg | |
| GMP-Bios-INN-1471-100mg | 100mg | |
| GMP-Bios-INN-1471-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Zamubafusp biosimilar, Antibody Fusion Protein: Recombinant therapeutic protein targeting Human variable immunoglobulin light chain (N-terminal cryptic neo-epitope) |
| INN Name | Zamubafusp |
| Target | Human variable immunoglobulin light chain (N-terminal cryptic neo-epitope) |
| Format | Antibody Fusion Protein |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
